These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
519 related articles for article (PubMed ID: 25199050)
1. CXCL12+ stromal cells as bone marrow niche for CD34+ hematopoietic cells and their association with disease progression in myelodysplastic syndromes. Abe-Suzuki S; Kurata M; Abe S; Onishi I; Kirimura S; Nashimoto M; Murayama T; Hidaka M; Kitagawa M Lab Invest; 2014 Nov; 94(11):1212-23. PubMed ID: 25199050 [TBL] [Abstract][Full Text] [Related]
2. Apoptosis, bcl-2 expression and p53 accumulation in myelodysplastic syndrome, myelodysplastic-syndrome-derived acute myelogenous leukemia and de novo acute myelogenous leukemia. Kurotaki H; Tsushima Y; Nagai K; Yagihashi S Acta Haematol; 2000; 102(3):115-23. PubMed ID: 10692673 [TBL] [Abstract][Full Text] [Related]
3. The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Parker JE; Mufti GJ; Rasool F; Mijovic A; Devereux S; Pagliuca A Blood; 2000 Dec; 96(12):3932-8. PubMed ID: 11090080 [TBL] [Abstract][Full Text] [Related]
4. Distinctive contact between CD34+ hematopoietic progenitors and CXCL12+ CD271+ mesenchymal stromal cells in benign and myelodysplastic bone marrow. Flores-Figueroa E; Varma S; Montgomery K; Greenberg PL; Gratzinger D Lab Invest; 2012 Sep; 92(9):1330-41. PubMed ID: 22710983 [TBL] [Abstract][Full Text] [Related]
5. De novo AML exhibits greater microenvironment dysregulation compared to AML with myelodysplasia-related changes. Lopes MR; Pereira JK; de Melo Campos P; Machado-Neto JA; Traina F; Saad ST; Favaro P Sci Rep; 2017 Jan; 7():40707. PubMed ID: 28084439 [TBL] [Abstract][Full Text] [Related]
6. Analysis of CD34-positive cells in bone marrow from patients with myelodysplastic syndromes and acute myeloid leukemia and in normal individuals: a comparison between FACS analysis and immunohistochemistry. Kanter-Lewensohn L; Hellström-Lindberg E; Kock Y; Elmhorn-Rosenborg A; Ost A Eur J Haematol; 1996 Mar; 56(3):124-9. PubMed ID: 8598230 [TBL] [Abstract][Full Text] [Related]
7. Coexistence of aberrant hematopoietic and stromal elements in myelodysplastic syndromes. Abbas S; Kini A; Srivastava VM; M MT; Nair SC; Abraham A; Mathews V; George B; Kumar S; Venkatraman A; Srivastava A Blood Cells Mol Dis; 2017 Jul; 66():37-46. PubMed ID: 28822917 [TBL] [Abstract][Full Text] [Related]
9. MDS and AML show elevated fractions of CD34-positive blast cell populations with a high anti-apoptotic versus proliferation ratio. Mestrum SGC; Roanalis BYV; de Wit NCJ; Drent RJM; Boonen BT; van Hemert WLW; Hopman AHN; Ramaekers FCS; Leers MPG Leuk Res; 2024 Jul; 142():107520. PubMed ID: 38776565 [TBL] [Abstract][Full Text] [Related]
10. GATA-1 transcription factor is up-regulated in bone marrow hematopoietic progenitor CD34(+) and erythroid CD71(+) cells in myelodysplastic syndromes. Maratheftis CI; Bolaraki PE; Voulgarelis M Am J Hematol; 2007 Oct; 82(10):887-92. PubMed ID: 17570514 [TBL] [Abstract][Full Text] [Related]
11. Alteration of c-mpl-mediated signal transduction in CD34(+) cells from patients with myelodysplastic syndromes. Kalina U; Hofmann WK; Koschmieder S; Wagner S; Kauschat D; Hoelzer D; Ottmann OG Exp Hematol; 2000 Oct; 28(10):1158-63. PubMed ID: 11027834 [TBL] [Abstract][Full Text] [Related]
12. RepSox slows decay of CD34+ acute myeloid leukemia cells and decreases T cell immunoglobulin mucin-3 expression. Jajosky AN; Coad JE; Vos JA; Martin KH; Senft JR; Wenger SL; Gibson LF Stem Cells Transl Med; 2014 Jul; 3(7):836-48. PubMed ID: 24855276 [TBL] [Abstract][Full Text] [Related]
13. Expression of CDKN1C in the bone marrow of patients with myelodysplastic syndrome and secondary acute myeloid leukemia is associated with poor survival after conventional chemotherapy. Radujkovic A; Dietrich S; Andrulis M; Benner A; Longerich T; Pellagatti A; Nanda K; Giese T; Germing U; Baldus S; Boultwood J; Ho AD; Dreger P; Luft T Int J Cancer; 2016 Sep; 139(6):1402-13. PubMed ID: 27170453 [TBL] [Abstract][Full Text] [Related]
14. [Expression of Fas, FasL and Bcl-2 and apoptosis of bone marrow CD34+ cells in patients with myelodysplastic syndrome]. Zhang Z; Xie J Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Jun; 11(3):274-7. PubMed ID: 12844412 [TBL] [Abstract][Full Text] [Related]
15. Over-expression of cancerous inhibitor of PP2A (CIP2A) in bone marrow cells from patients with a group of high-risk myelodysplastic syndromes. Li N; Abe S; Kurata M; Abe-Suzuki S; Onishi I; Kirimura S; Murayama T; Hidaka M; Kawano F; Kitagawa M Pathol Oncol Res; 2014 Apr; 20(2):399-407. PubMed ID: 24163288 [TBL] [Abstract][Full Text] [Related]
16. Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes. Bouscary D; De Vos J; Guesnu M; Jondeau K; Viguier F; Melle J; Picard F; Dreyfus F; Fontenay-Roupie M Leukemia; 1997 Jun; 11(6):839-45. PubMed ID: 9177438 [TBL] [Abstract][Full Text] [Related]
17. The functional interplay of transcription factors and cell adhesion molecules in experimental myelodysplasia including hematopoietic stem progenitor compartment. Daw S; Law S Mol Cell Biochem; 2021 Feb; 476(2):535-551. PubMed ID: 33011884 [TBL] [Abstract][Full Text] [Related]
18. Cytogenetic analysis of CD34+ subpopulations in AML and MDS characterized by the expression of CD38 and CD117. Haase D; Feuring-Buske M; Schäfer C; Schoch C; Troff C; Gahn B; Hiddemann W; Wörmann B Leukemia; 1997 May; 11(5):674-9. PubMed ID: 9180291 [TBL] [Abstract][Full Text] [Related]
19. [Expression and Significance of Shh Signaling Pathway in Bone Marrow CD34 Qin YT; Yao L; Yin Z; Chen S; Wang H; Fan WX; Jiang M; Hao JP Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Oct; 28(5):1637-1642. PubMed ID: 33067966 [TBL] [Abstract][Full Text] [Related]
20. ASXL1 mutation as a surrogate marker in acute myeloid leukemia with myelodysplasia-related changes and normal karyotype. Prats-Martín C; Burillo-Sanz S; Morales-Camacho RM; Pérez-López O; Suito M; Vargas MT; Caballero-Velázquez T; Carrillo-Cruz E; González J; Bernal R; Pérez-Simón JA Cancer Med; 2020 Jun; 9(11):3637-3646. PubMed ID: 32216059 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]